Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
82,200
+500 (0.61%)
At close: Dec 5, 2025
Market Cap 1.74T
Revenue (ttm) 25.48M
Net Income (ttm) -36.88B
Shares Out 21.16M
EPS (ttm) -2,048.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 793,509
Average Volume 393,170
Open 81,600
Previous Close 81,700
Day's Range 74,500 - 84,500
52-Week Range 15,950 - 84,500
Beta n/a
RSI 81.51
Earnings Date Nov 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.